Literature DB >> 31074870

Eculizumab: A Complementary addition to existing long-term therapies for myasthenia gravis.

Christyn Edmundson1, Amanda C Guidon2.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2019        PMID： 31074870     DOI： 10.1002/mus.26512

Source DB:  PubMed          Journal:  Muscle Nerve        ISSN： 0148-639X            Impact factor:   3.217


× No keyword cloud information.
  2 in total

Review 1.  Practical Management for Use of Eculizumab in the Treatment of Severe, Refractory, Non-Thymomatous, AChR + Generalized Myasthenia Gravis: A Systematic Review.

Authors:  Waqar Waheed; Eric Newman; Marwa Aboukhatwa; Maryam Moin; Rup Tandan
Journal:  Ther Clin Risk Manag       Date:  2022-07-12       Impact factor: 2.755

2.  Suitable indications of eculizumab for patients with refractory generalized myasthenia gravis.

Authors:  Munenori Oyama; Kensuke Okada; Masayuki Masuda; Yuko Shimizu; Kazumasa Yokoyama; Akiyuki Uzawa; Naoki Kawaguchi; Ryotaro Ikeguchi; Yasunobu Hoshino; Taku Hatano; Yukiko Ozawa; Jin Nakahara; Hitoshi Aizawa; Kazuo Kitagawa; Nobutaka Hattori; Satoshi Kuwabara; Hiroyuki Murai; Shigeaki Suzuki
Journal:  Ther Adv Neurol Disord       Date:  2020-03-18       Impact factor: 6.570
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.